title: Cystic fibrosis-related dyslipidemia.
abstract: This article aims to review the physiopathology, diagnosis and treatment of cystic fibrosis-related dyslipidemia (CFD). Bibliographic searches of the Medline and Latin American and Caribbean Health Sciences Literature databases were made (year range, 1987-2007), and the most representative papers on the theme were selected. The characteristic symptoms of CFD are hypertriglyceridemia-with or without hypocholesterolemia-and essential fatty acid deficiency. The principal CFD risk factors are pancreatic insufficiency, high-carbohydrate diet, liver diseases, inflammatory state and corticosteroid therapy. There are no specific recommendations regarding screening, which is typically performed based on the diagnosis, and at regular intervals, and more frequently in individuals belonging to high-risk groups. Treatment includes a balanced diet, micronutrient supplementation, and regular physical exercise according to individual tolerance. In the great majority of the cases, CFD-related hypertriglyceridemia does not reach values for which the use of hypolipidemic drugs is indicated. We conclude that there are few articles in the literature regarding the frequency, etiology and management of CFD. Preventive and therapeutic recommendations for hypertriglyceridemia are extrapolated from studies in individuals without cystic fibrosis. Further research is necessary to investigate the association of essential fatty acid deficiency and the physiopathology of cystic fibrosis . Since hypertriglyceridemia is an important risk factor for coronary artery disease, prospective studies will contribute for a better understanding of the natural history of this condition and define how to prevent and treat it.
authors.affiliation: Universidade Federal da Bahia, Salvador, BA, Brasil. cresio.alves@uol.com.br
authors.forename: Crésio de Aragão Dantas
authors.initials: Cde A
authors.lastname: Alves
authors.forename: Daniela Seabra
authors.initials: DS
authors.lastname: Lima
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002784:Cholesterol / Q000097:blood; D003550:Cystic Fibrosis / Q000150:complications* / Q000378:metabolism; D004041:Dietary Fats / Q000378:metabolism; D050171:Dyslipidemias / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy; D005228:Fatty Acids, Essential / Q000172:deficiency / Q000378:metabolism; D006801:Humans; D015228:Hypertriglyceridemia / Q000503:physiopathology; D050356:Lipid Metabolism / Q000502:physiology; D012016:Reference Values; D014280:Triglycerides / Q000097:blood; D055815:Young Adult
chemical_list: D004041:Dietary Fats; D005228:Fatty Acids, Essential; D014280:Triglycerides; D002784:Cholesterol